Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Xencor, Inc. - Common Stock (NQ:XNCR)

15.97 +0.42 (+2.70%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 22, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 583,134
Open 15.49
Bid (Size) 15.94 (2,000)
Ask (Size) 15.96 (5,800)
Prev. Close 15.55
Today's Range 15.30 - 16.17
52wk Range 6.920 - 24.94
Shares Outstanding 59,924,016
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Xencor Announces Extension of U.S. Patent Term on Certain Xtend™ Antibodies
From Xencor, Inc.
Via Business Wire
News headline image
Xencor to Participate at Upcoming Investor Conferences
From Xencor, Inc.
Via Business Wire

Performance

YTD
-32.9%
-32.9%
1 Month
+0.6%
+0.6%
3 Month
+53.7%
+53.7%
6 Month
+89.9%
+89.9%
1 Year
-35.0%
-35.0%

More News

Read More
News headline image
Xencor Reports Third Quarter 2025 Financial Results
From Xencor, Inc.
Via Business Wire
News headline image
Xencor Presents Initial Data for XmAb819, a First-in-class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Clear Cell Renal Cell Carcinoma
From Xencor, Inc.
Via Business Wire
News headline image
Beyond The Numbers: 4 Analysts Discuss Xencor Stock ↗
Via Benzinga
News headline image
Xencor to Host Webcast and Conference Call to Discuss Initial Results from the Ongoing Phase 1 Dose-Escalation Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma
From Xencor, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
Via Benzinga
News headline image
Xencor Announces Presentation of Initial Phase 1 Dose-Escalation Results of XmAb819 in Clear Cell Renal Cell Carcinoma at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
From Xencor, Inc.
Via Business Wire
News headline image
Critical Insights From Xencor Analyst Ratings: What You Need To Know ↗
Via Benzinga
News headline image
Xencor to Participate at Upcoming Investor Conferences
From Xencor, Inc.
Via Business Wire
News headline image
Xencor (XNCR) Q2 Revenue Jumps 82% ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Xencor Reports Second Quarter 2025 Financial Results
From Xencor, Inc.
Via Business Wire
News headline image
Xencor Appoints Raymond Deshaies, Ph.D., to Board of Directors
From Xencor, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
Via Benzinga
News headline image
Xencor Reports First Quarter 2025 Financial Results
From Xencor, Inc.
Via Business Wire
News headline image
Xencor Announces Positive Interim Results From First-in-Human Healthy Volunteer Study of XmAb942, a High-Potency Extended Half-Life Anti-TL1A Antibody, in Development for Treatment of Inflammatory Bowel Disease
From Xencor, Inc.
Via Business Wire
News headline image
Xencor Appoints Todd Simpson to Board of Directors
From Xencor, Inc.
Via Business Wire
News headline image
Xencor Reports Fourth Quarter and Full Year 2024 Financial Results
From Xencor, Inc.
Via Business Wire
News headline image
Eliminating Some Screened Stocks ↗
Via Talk Markets
Topics Stocks / Equities
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
Via Benzinga
News headline image
Xencor to Participate at Upcoming Investor Conferences
From Xencor, Inc.
Via Business Wire
News headline image
Xencor Reports Third Quarter 2024 Financial Results
From Xencor, Inc.
Via Business Wire
News headline image
Xencor Doses First Subject in Phase 1/2 Study of XmAb®942 in Development for Patients with Inflammatory Bowel Disease
From Xencor, Inc.
Via Business Wire
News headline image
Xencor Presents Preclinical Data on XmAb942, a High-Potency Extended Half-Life Anti-TL1A Antibody, to be Developed for Patients with Inflammatory Bowel Diseases
From Xencor, Inc.
Via Business Wire

Frequently Asked Questions

Is Xencor, Inc. - Common Stock publicly traded?
Yes, Xencor, Inc. - Common Stock is publicly traded.
What exchange does Xencor, Inc. - Common Stock trade on?
Xencor, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Xencor, Inc. - Common Stock?
The ticker symbol for Xencor, Inc. - Common Stock is XNCR on the Nasdaq Stock Market
What is the current price of Xencor, Inc. - Common Stock?
The current price of Xencor, Inc. - Common Stock is 15.97
When was Xencor, Inc. - Common Stock last traded?
The last trade of Xencor, Inc. - Common Stock was at 12/22/25 04:00 PM ET
What is the market capitalization of Xencor, Inc. - Common Stock?
The market capitalization of Xencor, Inc. - Common Stock is 956.99M
How many shares of Xencor, Inc. - Common Stock are outstanding?
Xencor, Inc. - Common Stock has 957M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.